{"product_id":"handbook-of-healthcare-analytics-9781119300946","title":"Handbook of Healthcare Analytics","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cp\u003e\u003cb\u003eHow can analytics scholars and healthcare professionals access the most exciting and important healthcare topics and tools for the 21\u003csup\u003est\u003c\/sup\u003e century?\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eEditors Tinglong Dai and Sridhar Tayur, aided by a team of internationally acclaimed experts, have curated this timely volume to help newcomers and seasoned researchers alike to rapidly comprehend a diverse set of thrusts and tools in this rapidly growing cross-disciplinary field. The \u003ci\u003eHandbook\u003c\/i\u003e covers a wide range of macro-, meso- and micro-level thrustssuch as market design, competing interests, global health,personalizedmedicine, residential care and concierge medicine, among othersand structures what has been a highly fragmented research area into a coherent scientific discipline.\u003c\/p\u003e \u003cp\u003eThe handbook also provides an easy-to-comprehend introduction to five essential research toolsMarkov decision process, game theory and information economics, queueing games, econometric methods, and data scienceby illustrat\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003c\/p\u003e\u003cp\u003eList of Contributors xvii\u003c\/p\u003e \u003cp\u003ePreface xix\u003c\/p\u003e \u003cp\u003eGlossary of Terms xxvii\u003c\/p\u003e \u003cp\u003eAcknowledgments xxxv\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart I Thrusts Macro-level Thrusts (MaTs)\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1 Organizational Structure 1\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eJay Levine\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1.1 Introduction to the Healthcare Industry 2\u003c\/p\u003e \u003cp\u003e1.2 Academic Medical Centers 6\u003c\/p\u003e \u003cp\u003e1.3 Community Hospitals and Physicians 16\u003c\/p\u003e \u003cp\u003e1.4 Conclusion 19\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 Access to Healthcare 21\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eDonald R. Fischer\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2.1 Introduction 21\u003c\/p\u003e \u003cp\u003e2.2 Goals 27\u003c\/p\u003e \u003cp\u003e2.3 Opportunity for Action 29\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 Market Design 31\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eItai Ashlagi\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3.1 Introduction 31\u003c\/p\u003e \u003cp\u003e3.2 Matching Doctors to Residency Programs 31\u003c\/p\u003e \u003cp\u003e3.2.1 Early Days 31\u003c\/p\u003e \u003cp\u003e3.2.2 A Centralized Market and New Challenges 32\u003c\/p\u003e \u003cp\u003e3.2.3 Puzzles and Theory 33\u003c\/p\u003e \u003cp\u003e3.3 Kidney Exchange 35\u003c\/p\u003e \u003cp\u003e3.3.1 Background 35\u003c\/p\u003e \u003cp\u003e3.3.2 Creating a Thick Marketplace for Kidney Exchange 36\u003c\/p\u003e \u003cp\u003e3.3.3 Dynamic Matching 38\u003c\/p\u003e \u003cp\u003e3.3.4 The Marketplace for Kidney Exchange in the United States 41\u003c\/p\u003e \u003cp\u003e3.3.5 Final Comments on Kidney Exchange 43\u003c\/p\u003e \u003cp\u003eReferences 44\u003c\/p\u003e \u003cp\u003eMeso-level Thrusts (MeTs)\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 Competing Interests 51\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eJoel Goh\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4.1 Introduction 51\u003c\/p\u003e \u003cp\u003e4.2 The Literature on Competing Interests 53\u003c\/p\u003e \u003cp\u003e4.2.1 Evaluation of Pharmaceutical Products 53\u003c\/p\u003e \u003cp\u003e4.2.1.1 Individual Drug Classes 54\u003c\/p\u003e \u003cp\u003e4.2.1.2 Multiple Interventions 55\u003c\/p\u003e \u003cp\u003e4.2.1.3 Review Articles 56\u003c\/p\u003e \u003cp\u003e4.2.2 Physician Ownership 56\u003c\/p\u003e \u003cp\u003e4.2.2.1 Physician Ownership of Ancillary Services 57\u003c\/p\u003e \u003cp\u003e4.2.2.2 Physician Ownership of Ambulatory Surgery Centers 59\u003c\/p\u003e \u003cp\u003e4.2.2.3 Physician Ownership of Speciality Hospitals 60\u003c\/p\u003e \u003cp\u003e4.2.2.4 Physician-Owned Distributors 61\u003c\/p\u003e \u003cp\u003e4.2.3 Medical Reporting 62\u003c\/p\u003e \u003cp\u003e4.2.3.1 DRG Upcoding 63\u003c\/p\u003e \u003cp\u003e4.2.3.2 Non-DRG Upcoding 64\u003c\/p\u003e \u003cp\u003e4.3 Examples 65\u003c\/p\u003e \u003cp\u003e4.3.1 Example 1: Physician Decisions with Competing Interests 66\u003c\/p\u003e \u003cp\u003e4.3.2 Example 2: Evidence of HAI Upcoding 70\u003c\/p\u003e \u003cp\u003e4.4 Summary and FutureWork 72\u003c\/p\u003e \u003cp\u003eReferences 73\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 Quality of Care 79\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eHummy Song and Senthil Veeraraghavan\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5.1 Frameworks for Measuring Healthcare Quality 79\u003c\/p\u003e \u003cp\u003e5.1.1 The Donabedian Model 79\u003c\/p\u003e \u003cp\u003e5.1.2 The AHRQ Framework 81\u003c\/p\u003e \u003cp\u003e5.2 Understanding Healthcare Quality: Classification of the Existing\u003c\/p\u003e \u003cp\u003eOR\/MS Literature 82\u003c\/p\u003e \u003cp\u003e5.2.1 Structure 82\u003c\/p\u003e \u003cp\u003e5.2.2 Process 85\u003c\/p\u003e \u003cp\u003e5.2.3 Outcome 91\u003c\/p\u003e \u003cp\u003e5.2.4 Patient Experience 92\u003c\/p\u003e \u003cp\u003e5.2.5 Access 94\u003c\/p\u003e \u003cp\u003e5.3 Open Areas for Future Research 95\u003c\/p\u003e \u003cp\u003e5.3.1 Understanding Structures and Their Interactions with Processes and Outcomes 95\u003c\/p\u003e \u003cp\u003e5.3.2 Understanding Patient Experiences and Their Interactions with Structure 96\u003c\/p\u003e \u003cp\u003e5.3.3 Understanding Processes andTheir Interactions with Outcomes 97\u003c\/p\u003e \u003cp\u003e5.3.4 Understanding Access to Care 98\u003c\/p\u003e \u003cp\u003e5.4 Conclusions 98\u003c\/p\u003e \u003cp\u003eAcknowledgments 99\u003c\/p\u003e \u003cp\u003eReferences 99\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 Personalized Medicine 109\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eTurgay Ayer and Qiushi Chen\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6.1 Introduction 109\u003c\/p\u003e \u003cp\u003e6.2 Sequential Decision Disease Models with Health Information Updates 111\u003c\/p\u003e \u003cp\u003e6.2.1 Case Study: POMDP Model for Personalized Breast Cancer Screening 113\u003c\/p\u003e \u003cp\u003e6.2.2 Case Study: Kalman Filter for Glaucoma Monitoring 116\u003c\/p\u003e \u003cp\u003e6.2.3 Other Relevant Studies 118\u003c\/p\u003e \u003cp\u003e6.3 One-Time Decision Disease Models with Risk Stratification 120\u003c\/p\u003e \u003cp\u003e6.3.1 Case Study: Subtype-Based Treatment for DLBCL 121\u003c\/p\u003e \u003cp\u003e6.3.2 Other Applications 124\u003c\/p\u003e \u003cp\u003e6.4 Artificial Intelligence-Based Approaches 125\u003c\/p\u003e \u003cp\u003e6.4.1 Learning from Existing Health Data 126\u003c\/p\u003e \u003cp\u003e6.4.2 Learning from Trial and Error 127\u003c\/p\u003e \u003cp\u003e6.5 Conclusions and Emerging Future Research Directions 128\u003c\/p\u003e \u003cp\u003eReferences 130\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 Global Health 137\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eKarthik V. Natarajan and Jayashankar M. Swaminathan\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7.1 Introduction 137\u003c\/p\u003e \u003cp\u003e7.2 Funding Allocation in Global Health Settings 139\u003c\/p\u003e \u003cp\u003e7.2.1 Funding Allocation for Disease Prevention 139\u003c\/p\u003e \u003cp\u003e7.2.2 Funding Allocation for Treatment of Disease Conditions 143\u003c\/p\u003e \u003cp\u003e7.2.2.1 Service Settings 143\u003c\/p\u003e \u003cp\u003e7.2.2.2 Product Settings 146\u003c\/p\u003e \u003cp\u003e7.3 Inventory Allocation in Global Health Settings 147\u003c\/p\u003e \u003cp\u003e7.3.1 Inventory Allocation for Disease Prevention 147\u003c\/p\u003e \u003cp\u003e7.3.2 Inventory Allocation for Treatment of Disease Conditions 149\u003c\/p\u003e \u003cp\u003e7.4 Capacity Allocation in Global Health Settings 153\u003c\/p\u003e \u003cp\u003e7.5 Conclusions and Future Directions 155\u003c\/p\u003e \u003cp\u003eReferences 156\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 Healthcare Supply Chain 159\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eSoo-Haeng Cho and Hui Zhao\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8.1 Introduction 159\u003c\/p\u003e \u003cp\u003e8.2 Literature Review 162\u003c\/p\u003e \u003cp\u003e8.3 Model and Analysis 164\u003c\/p\u003e \u003cp\u003e8.3.1 Generic Injectable Drug Supply Chain 164\u003c\/p\u003e \u003cp\u003e8.3.1.1 Model 166\u003c\/p\u003e \u003cp\u003e8.3.1.2 Analysis 168\u003c\/p\u003e \u003cp\u003e8.3.2 Influenza Vaccine Supply Chain 171\u003c\/p\u003e \u003cp\u003e8.3.2.1 Model 172\u003c\/p\u003e \u003cp\u003e8.3.2.2 Analysis 173\u003c\/p\u003e \u003cp\u003e8.4 Discussion and Future Research 177\u003c\/p\u003e \u003cp\u003eAppendix 180\u003c\/p\u003e \u003cp\u003eAcknowledgment 182\u003c\/p\u003e \u003cp\u003eReferences 182\u003c\/p\u003e \u003cp\u003e\u003cb\u003e9 Organ Transplantation 187\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eBar\u003c\/i\u003e\u003ci\u003e𝚤¸s Ata, John J. Friedewald and A. CemRanda\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9.1 Introduction 187\u003c\/p\u003e \u003cp\u003e9.2 The Deceased-Donor Organ Allocation system: Stakeholders and Their Objectives 189\u003c\/p\u003e \u003cp\u003e9.3 Research Opportunities in the Area 199\u003c\/p\u003e \u003cp\u003e9.3.1 Past Research on the Transplant Candidate’s Problem 199\u003c\/p\u003e \u003cp\u003e9.3.2 Challenges in Modeling Patient Choice 201\u003c\/p\u003e \u003cp\u003e9.3.3 Past Research on the Deceased-donor Organ Allocation Policy 202\u003c\/p\u003e \u003cp\u003e9.3.4 Challenges in Modeling the Deceased-donor Organ Allocation Policy 206\u003c\/p\u003e \u003cp\u003e9.3.5 Research Problems from the Perspective of Other Stakeholders 206\u003c\/p\u003e \u003cp\u003e9.4 Concluding Remarks 208\u003c\/p\u003e \u003cp\u003eReferences 209\u003c\/p\u003e \u003cp\u003eMicro-level Thrusts (MiTs)\u003c\/p\u003e \u003cp\u003e\u003cb\u003e10 Ambulatory Care 217\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eNan Liu\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10.1 Introduction 217\u003c\/p\u003e \u003cp\u003e10.2 How Operations are Managed in Primary Care Practice 218\u003c\/p\u003e \u003cp\u003e10.3 What Makes Operations Management Difficult in Ambulatory Care 220\u003c\/p\u003e \u003cp\u003e10.3.1 Competing Objectives 220\u003c\/p\u003e \u003cp\u003e10.3.2 Environmental Factors 221\u003c\/p\u003e \u003cp\u003e10.4 Operations Management Models 222\u003c\/p\u003e \u003cp\u003e10.4.1 System-Wide Planning 222\u003c\/p\u003e \u003cp\u003e10.4.2 Appointment Template Design 226\u003c\/p\u003e \u003cp\u003e10.4.3 Managing Patient Flow 231\u003c\/p\u003e \u003cp\u003e10.5 New Trends in Ambulatory Care 234\u003c\/p\u003e \u003cp\u003e10.5.1 Online Market 234\u003c\/p\u003e \u003cp\u003e10.5.2 Telehealth 235\u003c\/p\u003e \u003cp\u003e10.5.3 Retail Approach of Outpatient Care 236\u003c\/p\u003e \u003cp\u003e10.6 Conclusion 237\u003c\/p\u003e \u003cp\u003eReferences 237\u003c\/p\u003e \u003cp\u003e\u003cb\u003e11 Inpatient Care 243\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eVan-Anh Truong\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e11.1 Modeling the Inpatient Ward 244\u003c\/p\u003e \u003cp\u003e11.2 Inpatient Ward Policies 246\u003c\/p\u003e \u003cp\u003e11.3 Interface with ED 247\u003c\/p\u003e \u003cp\u003e11.4 Interface with Elective Surgeries 248\u003c\/p\u003e \u003cp\u003e11.5 Discharge Planning 250\u003c\/p\u003e \u003cp\u003e11.6 Incentive, Behavioral, and Organizational Issues 251\u003c\/p\u003e \u003cp\u003e11.7 Future Directions 252\u003c\/p\u003e \u003cp\u003e11.7.1 Essential Quantitative Tools 253\u003c\/p\u003e \u003cp\u003e11.7.2 Resources for Learners 253\u003c\/p\u003e \u003cp\u003eReferences 253\u003c\/p\u003e \u003cp\u003e\u003cb\u003e12 Residential Care 257\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eNadia Lahrichi, Louis-Martin Rousseau and Willem-Jan van Hoeve\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e12.1 Overview of Home Care Delivery 257\u003c\/p\u003e \u003cp\u003e12.1.1 Home Care 258\u003c\/p\u003e \u003cp\u003e12.1.2 Home Healthcare 258\u003c\/p\u003e \u003cp\u003e12.1.2.1 Temporary Care 259\u003c\/p\u003e \u003cp\u003e12.1.2.2 Specialized Programs 259\u003c\/p\u003e \u003cp\u003e12.1.3 Operational Challenges 260\u003c\/p\u003e \u003cp\u003e12.1.3.1 Discussion of the Planning Horizon 262\u003c\/p\u003e \u003cp\u003e12.1.3.2 Home Care Planning Problem 263\u003c\/p\u003e \u003cp\u003e12.2 An Overview of Optimization Technology 263\u003c\/p\u003e \u003cp\u003e12.2.1 Linear Programming 263\u003c\/p\u003e \u003cp\u003e12.2.2 Mixed Integer Programming 264\u003c\/p\u003e \u003cp\u003e12.2.3 Constraint Programming 265\u003c\/p\u003e \u003cp\u003e12.2.4 Heuristics and Dedicated Methods 265\u003c\/p\u003e \u003cp\u003e12.2.5 Technology Comparison 266\u003c\/p\u003e \u003cp\u003e12.2.5.1 Solution Expectations and Solver Capabilities 266\u003c\/p\u003e \u003cp\u003e12.2.5.2 Development Time and Maintenance 267\u003c\/p\u003e \u003cp\u003e12.3 Territory Districting 267\u003c\/p\u003e \u003cp\u003e12.4 Provider-to-Patient Assignment 270\u003c\/p\u003e \u003cp\u003e12.4.1 Workload Measures 270\u003c\/p\u003e \u003cp\u003e12.4.2 Workload Balance 271\u003c\/p\u003e \u003cp\u003e12.4.3 Assignment Models 272\u003c\/p\u003e \u003cp\u003e12.4.4 Assignment of New Patients 273\u003c\/p\u003e \u003cp\u003e12.5 Task Scheduling and Routing 273\u003c\/p\u003e \u003cp\u003e12.6 Perspectives 276\u003c\/p\u003e \u003cp\u003e12.6.1 Integrated Decision-Making Under a New Business Model 277\u003c\/p\u003e \u003cp\u003e12.6.2 Home Telemetering Forecasting Adverse Events 277\u003c\/p\u003e \u003cp\u003e12.6.3 Forecasting the Wound Healing Process 278\u003c\/p\u003e \u003cp\u003e12.6.4 Adjustment of Capacity and Demand 279\u003c\/p\u003e \u003cp\u003eReferences 280\u003c\/p\u003e \u003cp\u003e\u003cb\u003e13 ConciergeMedicine 287\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eSrinagesh Gavirneni and Vidyadhar G. Kulkarni\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e13.1 Introduction 287\u003c\/p\u003e \u003cp\u003e13.2 Model Setup 291\u003c\/p\u003e \u003cp\u003e13.3 Concierge Option—No Abandonment 293\u003c\/p\u003e \u003cp\u003e13.3.1 A Given Participation Level 𝛼 294\u003c\/p\u003e \u003cp\u003e13.3.2 How to choose d? 295\u003c\/p\u003e \u003cp\u003e13.3.2.1 All Customers Are Better Off 295\u003c\/p\u003e \u003cp\u003e13.3.2.2 Customers Are Better Off on Average 297\u003c\/p\u003e \u003cp\u003e13.3.3 Optimal Participation Level 299\u003c\/p\u003e \u003cp\u003e13.4 Concierge Option—Abandonment 301\u003c\/p\u003e \u003cp\u003e13.4.1 Choosing the Optimal 𝛼 and 𝛽 303\u003c\/p\u003e \u003cp\u003e13.5 Correlated Service Times and Waiting Costs 304\u003c\/p\u003e \u003cp\u003e13.6 MDVIP Adoption 306\u003c\/p\u003e \u003cp\u003e13.6.1 The Data 307\u003c\/p\u003e \u003cp\u003e13.6.2 AbandonmentModel Applied to MDVIP Data 308\u003c\/p\u003e \u003cp\u003e13.6.2.1 Modeling Heterogeneous Waiting Costs 309\u003c\/p\u003e \u003cp\u003e13.6.2.2 Participation in Concierge Medicine 310\u003c\/p\u003e \u003cp\u003e13.6.2.3 Impact of Concierge Medicine 310\u003c\/p\u003e \u003cp\u003e13.6.2.4 Choosing the Concierge Participation Level 312\u003c\/p\u003e \u003cp\u003e13.7 Research Opportunities 313\u003c\/p\u003e \u003cp\u003eReferences 316\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart II Tools\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e14 Markov Decision Processes 319\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eAlan Scheller-Wolf\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e14.1 Introduction 319\u003c\/p\u003e \u003cp\u003e14.2 Modeling 321\u003c\/p\u003e \u003cp\u003e14.3 Types of Results 325\u003c\/p\u003e \u003cp\u003e14.3.1 Numerical Results 325\u003c\/p\u003e \u003cp\u003e14.3.2 Analytical Results 327\u003c\/p\u003e \u003cp\u003e14.3.3 Insights 328\u003c\/p\u003e \u003cp\u003e14.4 Modifications and Extensions of MDPs 328\u003c\/p\u003e \u003cp\u003e14.4.1 Imperfect State Information 328\u003c\/p\u003e \u003cp\u003e14.4.2 Extremely Large or Continuous State Spaces 329\u003c\/p\u003e \u003cp\u003e14.4.3 Uncertainty about Transition Probabilities 330\u003c\/p\u003e \u003cp\u003e14.4.4 Constrained Optimization 331\u003c\/p\u003e \u003cp\u003e14.5 Future Applications 332\u003c\/p\u003e \u003cp\u003e14.6 Recommendations for Additional Reading 333\u003c\/p\u003e \u003cp\u003eReferences 334\u003c\/p\u003e \u003cp\u003e\u003cb\u003e15 Game Theory and Information Economics 337\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eTinglong Dai\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e15.1 Introduction 337\u003c\/p\u003e \u003cp\u003e15.2 Key Concepts 339\u003c\/p\u003e \u003cp\u003e15.2.1 GameTheory: Key Concepts 339\u003c\/p\u003e \u003cp\u003e15.2.2 Information Economics: Key Concepts 340\u003c\/p\u003e \u003cp\u003e15.2.2.1 Nonobservability of Information 341\u003c\/p\u003e \u003cp\u003e15.2.2.2 Asymmetric Information 341\u003c\/p\u003e \u003cp\u003e15.3 Summary of Healthcare Applications 343\u003c\/p\u003e \u003cp\u003e15.3.1 Incentive Design for Healthcare Providers 344\u003c\/p\u003e \u003cp\u003e15.3.2 Quality-Speed Tradeoff 345\u003c\/p\u003e \u003cp\u003e15.3.3 Gatekeepers 346\u003c\/p\u003e \u003cp\u003e15.3.4 Healthcare Supply Chain 346\u003c\/p\u003e \u003cp\u003e15.3.5 Vaccination 346\u003c\/p\u003e \u003cp\u003e15.3.6 Organ Transplantation 347\u003c\/p\u003e \u003cp\u003e15.3.7 Healthcare Network 347\u003c\/p\u003e \u003cp\u003e15.3.8 Mixed Motives of Healthcare Providers 347\u003c\/p\u003e \u003cp\u003e15.4 Potential Applications 348\u003c\/p\u003e \u003cp\u003e15.4.1 Micro-Level applications 348\u003c\/p\u003e \u003cp\u003e15.4.2 Macro-Level Applications 349\u003c\/p\u003e \u003cp\u003e15.4.3 Meso-Level Applications 349\u003c\/p\u003e \u003cp\u003e15.5 Resources for Learners 351\u003c\/p\u003e \u003cp\u003eReferences 351\u003c\/p\u003e \u003cp\u003e\u003cb\u003e16 Queueing Games 355\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eMustafa Akan\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e16.1 Introduction 355\u003c\/p\u003e \u003cp\u003e16.1.1 Scope of the Review 356\u003c\/p\u003e \u003cp\u003e16.2 Basic QueueingModels 356\u003c\/p\u003e \u003cp\u003e16.2.1 Components of a Queueing System 356\u003c\/p\u003e \u003cp\u003e16.2.2 Performance Measures 357\u003c\/p\u003e \u003cp\u003e16.2.3 M\/M\/1 358\u003c\/p\u003e \u003cp\u003e16.2.4 M\/G\/1 359\u003c\/p\u003e \u003cp\u003e16.2.5 M\/M\/c 360\u003c\/p\u003e \u003cp\u003e16.2.6 Priorities 361\u003c\/p\u003e \u003cp\u003e16.2.6.1 Achievable Region Approach 363\u003c\/p\u003e \u003cp\u003e16.2.7 Networks of Queues 364\u003c\/p\u003e \u003cp\u003e16.2.8 Approximations 364\u003c\/p\u003e \u003cp\u003e16.3 Strategic Queueing 365\u003c\/p\u003e \u003cp\u003e16.3.1 Waiting as an Equilibrium Device 366\u003c\/p\u003e \u003cp\u003e16.3.2 Demand Dependent on Service Time 367\u003c\/p\u003e \u003cp\u003e16.3.3 Physician-Induced Demand 369\u003c\/p\u003e \u003cp\u003e16.3.4 Joining the Queue 370\u003c\/p\u003e \u003cp\u003e16.3.4.1 Observable Queue 370\u003c\/p\u003e \u003cp\u003e16.3.4.2 Unobservable Queue 371\u003c\/p\u003e \u003cp\u003e16.3.5 Waiting for a Better Match 373\u003c\/p\u003e \u003cp\u003e16.4 Discussion and Future Research Directions 376\u003c\/p\u003e \u003cp\u003eReferences 376\u003c\/p\u003e \u003cp\u003e\u003cb\u003e17 EconometricMethods 381\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eDiwas KC\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e17.1 Introduction 381\u003c\/p\u003e \u003cp\u003e17.2 Statistical Modeling 382\u003c\/p\u003e \u003cp\u003e17.2.1 Statistical Inference 383\u003c\/p\u003e \u003cp\u003e17.2.2 Biased Estimates 384\u003c\/p\u003e \u003cp\u003e17.3 The Experimental Ideal and the Search for Exogenous Variation 386\u003c\/p\u003e \u003cp\u003e17.3.1 Instrumental Variables 386\u003c\/p\u003e \u003cp\u003e17.3.1.1 Example 1 (IV): Patient Flow through an Intensive Care Unit 388\u003c\/p\u003e \u003cp\u003e17.3.1.2 Example 2 (IV): Focused Factories 391\u003c\/p\u003e \u003cp\u003e17.3.2 Difference Estimators 392\u003c\/p\u003e \u003cp\u003e17.3.3 Fixed Effects Estimators 394\u003c\/p\u003e \u003cp\u003e17.3.3.1 Examples 3-4 (D-in-D): Process Compliance and Peer Effects of Productivity 395\u003c\/p\u003e \u003cp\u003e17.4 Structural Estimation 395\u003c\/p\u003e \u003cp\u003e17.4.1 Example 5: Managing Operating Room Capacity 396\u003c\/p\u003e \u003cp\u003e17.4.2 Example 6: Patient Choice Modeling 397\u003c\/p\u003e \u003cp\u003e17.5 Conclusion 399\u003c\/p\u003e \u003cp\u003eReferences 400\u003c\/p\u003e \u003cp\u003e\u003cb\u003e18 Data Science 403\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eRema Padman\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e18.1 Introduction 403\u003c\/p\u003e \u003cp\u003e18.1.1 Background 404\u003c\/p\u003e \u003cp\u003e18.1.2 Methods 407\u003c\/p\u003e \u003cp\u003e18.1.3 Attribute Selection and Ranking 408\u003c\/p\u003e \u003cp\u003e18.1.4 Information Gain (IG) Attribute Ranking 408\u003c\/p\u003e \u003cp\u003e18.1.5 Relief-F Attribute Ranking 408\u003c\/p\u003e \u003cp\u003e18.1.6 Markov Blanket Feature Selection 408\u003c\/p\u003e \u003cp\u003e18.1.7 Correlation-Based Feature Selection 409\u003c\/p\u003e \u003cp\u003e18.1.8 Classification 409\u003c\/p\u003e \u003cp\u003e18.2 Three Illustrative Examples of Data Science in Healthcare 410\u003c\/p\u003e \u003cp\u003e18.2.1 Medication Reconciliation 410\u003c\/p\u003e \u003cp\u003e18.2.2 Dynamic Prediction of Medical Risks 413\u003c\/p\u003e \u003cp\u003e18.2.3 Practice-Based Clinical Pathway Learning 416\u003c\/p\u003e \u003cp\u003e18.3 Discussion 419\u003c\/p\u003e \u003cp\u003e18.3.1 Challenges and Opportunities 419\u003c\/p\u003e \u003cp\u003e18.3.2 Data Science in Action 420\u003c\/p\u003e \u003cp\u003e18.3.3 Health Data ScienceWorldwide 421\u003c\/p\u003e \u003cp\u003e18.4 Conclusions 421\u003c\/p\u003e \u003cp\u003eReferences 422\u003c\/p\u003e \u003cp\u003eIndex 429\u003c\/p\u003e","brand":"John Wiley \u0026 Sons Inc","offers":[{"title":"Default Title","offer_id":49407031083351,"sku":"9781119300946","price":100.76,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9781119300946.jpg?v=1730497936","url":"https:\/\/bookcurl.com\/products\/handbook-of-healthcare-analytics-9781119300946","provider":"Book Curl","version":"1.0","type":"link"}